title: The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.
abstract: In the present study, the interaction between the endocytic receptor low density lipoprotein receptor-related protein (LRP) and coagulation factor VIII (FVIII) was investigated. Using purified components, FVIII was found to bind to LRP in a reversible and dose-dependent manner (K(d) approximately 60 nM). The interaction appeared to be specific because the LRP antagonist receptor-associated protein readily inhibited binding of FVIII to LRP (IC(50) approximately 1 nM). In addition, a 12-fold molar excess of the physiological carrier of FVIII, i.e. von Willebrand factor (vWF), reduced the binding of FVIII to LRP by over 90%. Cellular degradation of (125)I-labeled FVIII by LRP-expressing cells ( approximately 8 fmol/10(5) cells after a 4.5-h incubation) was reduced by approximately 70% in the presence of receptor-associated protein. LRP-directed antibodies inhibited degradation to a similar extent, indicating that LRP indeed contributes to binding and transport of FVIII to the intracellular degradation pathway. Degradation of FVIII was completely inhibited by vWF. Because vWF binding by FVIII involves its light chain, LRP binding to this subunit was studied. In ligand blotting experiments, binding of FVIII light chain to LRP could be visualized. More detailed analysis revealed that FVIII light chain interacts with LRP with moderate affinity (k(on) approximately 5 x 10(4) M(-1) s(-1); k(off) approximately 2.5 x 10(-3) s(-1); K(d) approximately 50 nM). Furthermore, experiments using recombinant FVIII C2 domain showed that this domain contributes to the interaction with LRP. In contrast, no association of FVIII heavy chain to LRP could be detected under the same experimental conditions. Collectively, our data demonstrate that in vitro LRP is able to bind FVIII at the cell surface and to mediate its transport to the intracellular degradation pathway. FVIII-LRP interaction involves the FVIII light chain, and FVIII-vWF complex formation plays a regulatory role in LRP binding. Our findings may explain the beneficial effect of vWF on the in vivo survival of FVIII.
authors.affiliation: Department of Plasma Protein Technology, CLB, 1066 CX Amsterdam The Netherlands. P_Lenting@clb.nl
authors.forename: P J
authors.initials: PJ
authors.lastname: Lenting
authors.forename: J G
authors.initials: JG
authors.lastname: Neels
authors.forename: B M
authors.initials: BM
authors.lastname: van den Berg
authors.forename: P P
authors.initials: PP
authors.lastname: Clijsters
authors.forename: D W
authors.initials: DW
authors.lastname: Meijerman
authors.forename: H
authors.initials: H
authors.lastname: Pannekoek
authors.forename: J A
authors.initials: JA
authors.lastname: van Mourik
authors.forename: K
authors.initials: K
authors.lastname: Mertens
authors.forename: A J
authors.initials: AJ
authors.lastname: van Zonneveld
mesh_terms: D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D016466:CHO Cells; D006224:Cricetinae; D005169:Factor VIII / Q000378:metabolism*; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D011971:Receptors, Immunologic / Q000378:metabolism*; D013917:Thrombin / Q000378:metabolism; D014841:von Willebrand Factor / Q000494:pharmacology
chemical_list: D026503:Low Density Lipoprotein Receptor-Related Protein-1; D011971:Receptors, Immunologic; D014841:von Willebrand Factor; D005169:Factor VIII; D013917:Thrombin